Chonnam Med J.  2019 Sep;55(3):156-162. 10.4068/cmj.2019.55.3.156.

Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues

• Ha JY
• Sung MS
• Park SW

• KMID: 2458568
• DOI: http://doi.org/10.4068/cmj.2019.55.3.156

Abstract

This study compared the effect of preservative-containing (PC) and preservative-free (PF) prostaglandin analogue (PGA) formulations on the ocular surface, especially on the meibomian gland (MG) in patients with open-angle glaucoma (OAG). This is a retrospective study of treatment-naïve patients with OAG (n=80) and healthy controls (n=40). OAG patients were randomized into groups using either PC-PGA or PF-PGA for 12 months. All participants underwent ocular surface and MG examinations including their meibum score, meiboscore, and lid margin abnormality score (LAS). Eighty OAG patients were randomized into two groups (n=42 in PC, n=38 in PF). All PGA and control groups showed similar ocular surface and MG parameters at the baseline. Both PC- and PF-PGA groups showed increased meibum scores, meiboscores, and LASs at 12 months compared to the baseline (all p<0.05). At the 12-months visit, PC-PGA group showed severe OSDI, shorter TBUT, greater OSS, and worse MG parameters than those of the other two groups (all p<0.05). In addition, PF-PGA group showed worse meiboscores, meibum scores, and severe OSS scores than those of the control group (all p<0.05). Both PC and PF formulations can cause damage to the MG in patients using PGA. However, PC formulations induced more ocular discomfort, poorer ocular surface, and more severe MG loss compared to PF formulations. Therefore, it would be advisable to use PF formulations in patients with a preexisting or concomitant ocular surface disease or MGD.

Keyword

Benzalkonium Compounds; Glaucoma; Meibomian Glands; Prostaglandins, Synthetic; Preservatives, Pharmaceutical

MeSH Terms

Benzalkonium Compounds
Glaucoma*
Glaucoma, Open-Angle
Humans
Meibomian Glands*
Preservatives, Pharmaceutical
Prostaglandins, Synthetic*
Retrospective Studies
Benzalkonium Compounds
Preservatives, Pharmaceutical
Prostaglandins, Synthetic

Figure

• 

  FIG. 1 Changes of ocular surface parameters during 12-months treatment. OSDI and OSS score were increased and TBUT was decreased in both PC-PGA and PF-PGA groups and reached significance at 12 months compared to the baseline (all *p<0.05). However, there was no significant change in Schirmer's test results during the 12 months of follow-up in all three groups.

• 

  FIG. 2 Changes of meibomian gland parameters during 12-months treatment. Both PC-PGA and PF-PGA groups showed increased meibum score, meiboscore, and LAS at 12 months compared to baseline (all *p<0.05). Further, meibum score and meiboscore at 9 months of PC-PGA group were higher than those at baseline (p=0.02 and p=0.01).

Reference

1. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008; 53 Suppl1:S69–S84.

2. Aydin Kurna S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study. J Ophthalmol. 2014; 2014:460483.

3. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011; 52:1922–1929.

4. Lee TH, Sung MS, Heo H, Park SW. Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS One. 2018; 13:e0191398.

5. Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016; 25:770–774.

6. Cho WH, Lai IC, Fang PC, Chien CC, Tseng SL, Lai YH, et al. Meibomian gland performance in glaucomatous patients with long-term instillation of IOP-lowering medications. J Glaucoma. 2018; 27:176–183.

7. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, et al. Effects of long-term topical anti-glaucoma medications on meibomian glands. Graefes Arch Clin Exp Ophthalmol. 2012; 250:1181–1185.

8. Rath A, Eichhorn M, Träger K, Paulsen F, Hampel U. In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells. Ann Anat. 2019; 222:129–138.

9. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008; 115:109–115.

10. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000; 118:615–621.

11. Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjögren syndrome. Ophthalmology. 1998; 105:1485–1488.

12. Rabinowitz MP, Katz LJ, Moster MR, Myers JS, Pro MJ, Spaeth GL, et al. Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthalmic Plast Reconstr Surg. 2015; 31:373–378.

13. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea. 2012; 31:1229–1234.

14. Ban Y, Shimazaki-Den S, Tsubota K, Shimazaki J. Morphological evaluation of meibomian glands using noncontact infrared meibography. Ocul Surf. 2013; 11:47–53.

15. Arita R, Suehiro J, Haraguchi T, Shirakawa R, Tokoro H, Amano S. Objective image analysis of the meibomian gland area. Br J Ophthalmol. 2014; 98:746–755.

16. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology. 2008; 115:911–915.

17. Cunniffe MG, Medel-Jiménez R, González-Candial M. Topical antiglaucoma treatment with prostaglandin analogues may precipitate meibomian gland disease. Ophthalmic Plast Reconstr Surg. 2011; 27:e128–e129.

18. Agnifili L, Fasanella V, Costagliola C, Ciabattoni C, Mastropasqua R, Frezzotti P, et al. In vivo confocal microscopy of meibomian glands in glaucoma. Br J Ophthalmol. 2013; 97:343–349.

19. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29:312–334.

20. Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018; 102:1497–1503.

21. Lee W, Lee S, Bae H, Kim CY, Seong GJ. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study. BMC Ophthalmol. 2017; 17:61.

22. Fasanella V, Agnifili L, Mastropasqua R, Brescia L, Di Staso F, Ciancaglini M, et al. In vivo laser scanning confocal microscopy of human meibomian glands in aging and ocular surface diseases. Biomed Res Int. 2016; 2016:7432131.

23. Agnifili L, Mastropasqua R, Fasanella V, Brescia L, Scatena B, Oddone F, et al. Meibomian gland features and conjunctival goblet cell density in glaucomatous patients controlled with prostaglandin/timolol fixed combinations: a case control, cross-sectional study. J Glaucoma. 2018; 27:364–370.

24. Uzunosmanoglu E, Mocan MC, Kocabeyoglu S, Karakaya J, Irkec M. Meibomian gland dysfunction in patients receiving long-term glaucoma medications. Cornea. 2016; 35:1112–1116.